Advancing Conjugated Therapeutics: From ADC Innovation to Integrated Bioanalysis Strategies

Conjugated therapeutics, including antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs), are reshaping the future of targeted therapies and driving new opportunities across oncology, immunotherapy, and precision medicine. As the field continues to evolve, researchers are increasingly focused on strategies to enhance efficacy, overcome drug resistance, and accelerate the development of next-generation conjugated therapeutics.

In our latest webinar, WuXi AppTec scientists share expert perspectives spanning ADC discovery, preclinical pharmacology, clinical bioanalysis, and DMPK strategies for AOCs. Viewers will gain insights into emerging approaches for next-generation ADC development, key clinical bioanalytical considerations, and integrated bioanalytical strategies that advance complex conjugated modalities.

Whether you’re developing ADCs, AOCs, or other conjugated therapeutics, this webinar explores key scientific considerations and practical strategies to help advance your programs.